


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147061901 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 11, 2003 Signature: 

(Melissa W. Acesta)

Docket No.: HO-P02288US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Patent Application of:  
George G. MacPherson, et al.

Application No.: 09/913,923

Confirmation No.:

Filed: February 17, 2000

Art Unit: N/A

For: ADJUVANT AND CELL MATURATION  
AGENT

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 09/913,923

Docket No.: HO-P02288US0

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02288US0. A duplicate copy of this paper is enclosed.

Dated: September 11, 2003

Respectfully submitted,



By  
Melissa W. Acosta  
Registration No.: 45,872  
FULBRIGHT & JAWORSKI L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-5151  
(713) 651-5246 (Fax)  
Attorney for Applicant



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	09/913,923
				<b>Filing Date</b>	February 17, 2000
				<b>First Named Inventor</b>	George G. MacPherson
				<b>Art Unit</b>	N/A
				<b>Examiner Name</b>	Not Yet Assigned
				<b>Attorney Docket Number</b>	HO-P02288US0
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	GB-2294321-A1	04-24-1996	Yamanouchi Research Institute		
	BB	DE-19802540-C1	11-19-1998	Klinikum der Albert-Ludwigs-Universität Freiburg		
	BC	WO-9853048-A1	11-26-1998	The Government of the United States of America - The Secretary of the department of Health and Human Services		
	BD	WO-9110683-A1	07-25-1991	The Blood Center of Southeastern Wisconsin, Inc.		
	BE	WO-9816245-A1	04-23-1998	Shionogi & Co.		
	BF	WO-9417184-A1	08-04-1994	Schering Corp.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Donaldson et al., "Localization of Antibody-Forming Cells in Draining Lymphoid Organs During Long-Term Maintenance of the Antibody Response," Journal of Leukocyte Biology 40; 1986; pp.147-157.	
	CB	Porgador et al., "Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization," The Journal of Experimental Medicine Vol. 188, No. 6, September 21, 1998, pp. 1075-1082.	
	CC	Toellner et al., "T Helper 1 (Th1) and Th2 Characteristics Start to Develop During T Cell Priming and Are Associated with an Immediate Ability to induce Immunoglobulin Class Switching," The Journal of Experimental Medicine Vol. 187 No 8, April 20, 1998, pp. 1193-1204.	
	CD	Jacob et al., "In Situ Studies of the Primary Immune Response to (4-hydroxy-3-nitrophenyl)acetyl. II. A Common Clonal Origin for Periaarteriolar Lymphoid Sheath-associated Foci and Germinal Centers," The Journal of Experimental Medicine Vol. 176, September 1992, pp. 679-687.	
	CE	Toellner et al., "Immunoglobulin Switch Transcript Production In Vivo Related to the Site and Time of Antigen-specific B Cell Activation," The Journal of Experimental Medicine Vol. 183, May 1996, pp. 2303-2312.	
	CF	Lui et al., "Sites of Specific B Cell Activation in Primary and Secondary Responses to T cell-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	09/913,923	
			Filing Date	February 17, 2000	
			First Named Inventor	George G. MacPherson	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	HO-P02288US0

		dependent and T cell-independent Antigens," Eur. J. Immunol. 21, 1991, pp. 2951-2962.	
	CG	Gray et al., "Memory B Cell Development but Not Germinal Center Formation is Impaired by In Vivo Blockade of CD40-CD40 Ligand Interaction," The Journal of Experimental Medicine Vol. 180, July 1994, pp. 141-155.	
	CH	van Essen et al., "CD40 Ligand-transduced Co-stimulation of T Cells in the Development of Helper Function," Nature Vol. 378, December 7, 1995, pp. 620 - 623.	
	CI	Franco et al., "Self-Aggregation of the Transmembrane Glycoprotein CD38 Purified from Human Erythrocytes," Biochemical and Biophysical Research Communications 1994, pp. 1710 - 1715.	
	CJ	Wykes et al., "Regulation of Cytoplasmic, Surface and Soluble Forms of CD40 Ligand in Mouse B Cells," Eur. J. Immunol. 28, 1998, pp.548-559.	
	CK	Kosco et al., "Follicular Dendritic Cell-Dependent Adhesion and Proliferation of B Cells In Vitro," The Journal of Immunology Vol. 148 No. 8; April 15, 1992, pp. 2331-2339.	
	CL	Lane et al., "Activated Human T Cells Express a Ligand for the Human B Cell-associated Antigen CD40 which Participates in T Cell-Dependent Activation of B Lymphocytes," Eur. J. Immunol. 22, 1992, pp.2573-2578.	
	CM	Harada et al., "Expression Cloning of a cDNA Encoding a Novel Murine B Cell Activation Marker," The Journal of Immunology Vol. 151 No. 6, September 15, 1993, pp. 3111-3118.	
	CN	Deaglio et al, "Human CD38 (ADP-Ribosyl Cyclase) is a Counter-Receptor of CD31, an Ig Superfamily Member," The Journal of Immunology 1998, pp. 395 - 402.	
	CO	Fernandez et al., "Analysis of the Distribution of Human CD38 and of its Ligand CD31 in Normal Tissues," Journal of Biological Regulators and Homeostatic Agents Vol. 12 No.3, pp. 81-91.	
	CP	Horenstein et al, "CD38 Binding to Human Myeloid Cells is Mediated by Mouse and Human CD31," Biochem J. 330, 1998, pp. 1129-1135.	
	CQ	Deaglio et al., "Human CD38 Ligand: A 120-KDA Protein Predominately Expressed on Endothelial Cells," The Journal of Immunology, 1996, pp. 727-734.	
	CR	Ellis et al., "Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma," The Journal of Immunology, 1995, pp. 925-935.	
	CS	Grouard et al., "Regulation of Human B Cell Activation by Follicular Dendritic Cell and T Cell Signals," Current Topics in Microbiology and Immunology 201, 1995, pp. 105-117.	
	CT	Wykes et al., "Dendritic Cells Interact Directly with Naive B Lymphocytes to Transfer Antigen and Initiate Class Switching in a Primary T-Dependent Response," The Journal of Immunology, 1998, pp.1313-1319.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------